Open an account

Ironwood Pharmaceuticals

IRWD · NASDAQ

$3.63+$0.07 (+1.97%)TodayMarket closed ·
Prev close $3.56

About IRWD

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Employees
100
Headquarters
Boston, Massachusetts
Listed
Feb 3, 2010
Sector
Health Care
Industry
Biotechnology
Website
ironwoodpharma.com

IRWD key statistics

Market cap
599.82M
Price-earnings ratio
4.62
Dividend yield
—
Average volume
1.98M
Volume
1.64M
Open price
$3.57
High today
$3.71
Low today
$3.53
52 Week high
$5.78
52 Week low
$1.44

Ironwood Pharmaceuticals (IRWD) at a glance

As of Oct 20, 2026, Ironwood Pharmaceuticals (IRWD) shares are priced at $3.63, giving the company a market cap of 599.82M and a price-to-earnings ratio of 4.62.

Today the stock has traded between $3.53 and $3.71. The current price is 3.0% above the day's low and 2.2% below its high.

Volume so far is 1.64M shares, in line with the average of 1.98M shares a day.

Over the past year Ironwood Pharmaceuticals has ranged from $1.44 to $5.78, and now sits 50% of the way up that range.

Ironwood Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $0.31 per share against an estimate of $0.3631.

The average analyst price target is $6.22, 71.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 6 analystsAvg $6.22
Low
$3.74
Now
$3.63
High
$10.50

IRWD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 189.2% on average.

  1. Q3 FY24: reported $0.02 per share against an estimate of $0.0822
  2. Q4 FY24: reported $0.02 per share against an estimate of $0.0798
  3. Q1 FY25: reported -$0.14 per share against an estimate of -$0.0476
  4. Q2 FY25: reported $0.14 per share against an estimate of $0.0408
  5. Q3 FY25: reported $0.24 per share against an estimate of $0.102
  6. Q4 FY25: reported -$0.01 per share against an estimate of $0.0102
  7. Q1 FY26: reported $0.24 per share against an estimate of $0.2448
  8. Q2 FY26: reported $0.31 per share against an estimate of $0.3631

IRWD news

  • Press releaseBusiness Wire

    Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

  • Press releaseBusiness Wire

    Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

  • Press releaseBusiness Wire

    Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

  • Press releaseBusiness Wire

    Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

  • Press releaseBusiness Wire

    Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

  • Press releaseBusiness Wire

    Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

  • Press releaseBusiness Wire

    FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

  • Press releaseBusiness Wire

    Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Similar companies

Companies in the same industry as Ironwood Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.